Biotech Top Gainers: OXiGENE (NASDAQ:OXGN), AEterna Zentaris (NASDAQ:AEZS), Marina Biotech (OTCMKTS:MRNA), Dicerna Pharmaceuticals (NASDAQ:DRNA)

Shares of Oxigene Inc (NASDAQ:OXGN) more than doubled on very heavy volume after the microcap biotech said a mid-stage study of its drug Zybrestat, when used with Roche’s Avastin, showed increased survival in ovarian cancer patients. OXiGENE Inc (NASDAQ:OXGN) stock performance was 17.48% in last session and finished the day at $2.42. Traded volume was 6,334,713 million shares in the last session and the average volume of the stock remained438.53 million shares. The beta of the stock remained 2.72. OXiGENE Inc (NASDAQ:OXGN) insider ownership is 0.10%.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on Feb. 4 announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) rose 16.41 percent to $1.49 yesterday on volume of 5.14 million shares. The intra-day range of the stock was $1.26 to $1.52. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has a market capitalization of $83.90million.

US RNAi-based drug discover Marina Biotech (Nasdaq:MRNA) says that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. Marina Biotech, Inc. (OTCMKTS:MRNA)’s stock on Mar 11, 2014 reported a increase of 16.67% to the closing price of $1.40. Its fifty two weeks range is $0.18 -$1.81. The total market capitalization recorded $22.91 million. The overall volume in the last trading session was 585,855 million shares. In its share capital, Marina Biotech, Inc. (OTCMKTS:MRNA) has 9.14million outstanding shares.

Zacks initiated coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research report issued to clients and investors on Wednesday, ARN reports. The firm set a “hold” rating on the stock. On Tuesday, shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) advanced 5.21% to close the day at $38.37. Company return on investment (ROI) is 16.60% and its monthly performance is recorded as 8.57%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone